Saisheng Pharmaceutical (6600.HK) 2023 Annual Performance Report Review: Ridaxian has a new high sales volume, and the research pipeline has great potential
西部證券Mar 28 00:00
Saisheng Pharmaceutical (6600.HK): Sales of Ridaxian continue to rise and gradually land in the research pipeline
西南證券Feb 18 16:21
Research Nuggets|Dongwu Securities: First qualifying Xisheng Pharmaceutical's “buy” rating, future dividend payments and repurchases are still the company's long-term strategy
Gelonghui FinanceFeb 4 14:25
Dongwu Securities: First qualifying Xisheng Pharmaceutical (06600) “buy” rating, the world's first oral SERD is expected to become a hot product
Zhitong FinanceFeb 2 14:47
Saisheng Pharmaceutical (06600.HK): Pharma, an established brand that innovates and adds kinetic energy, is setting sail
東吳證券Feb 2 12:36
Saisheng Pharmaceutical (6600.HK) covered for the first time: Ridaxen's continuous release of innovative drugs is remarkable
西部證券Jan 7 07:32
Saisheng Pharmaceutical (06600.HK): Valuation repair continues to be optimistic about Ridaxian's growth and the prospects for new pipelines
中金公司Dec 15, 2023 00:00
Saisheng Pharmaceutical (06600.HK): Leading mature pipelines for importing SERD drugs to accelerate expansion
中金公司Nov 7, 2023 18:42
Saisheng Pharmaceutical (06600.HK): Performance is in line with expectations Focus on the implementation of cooperative pipelines
中金公司Aug 19, 2023 00:00
Saisheng Pharmaceutical (06600.HK): Core business growth is in line with expectations, pipeline introduction progressed gradually
中金公司Mar 31, 2023 12:51
CICC: Maintains Saisen Pharmaceutical's (06600) “Outperform Industry” rating target price to HK$12.5
Zhitong FinanceMar 13, 2023 16:00
Saisheng Pharmaceutical (06600.HK): Stock repurchase completed, continued focus on valuation repair opportunities
中金公司Mar 13, 2023 14:33
Saisheng Pharmaceutical (06600.HK): Commercializing core varieties, experimenting with commercialization of bright new drugs
中金公司Aug 22, 2022 15:26
Saisheng Pharmaceutical (06600.HK): Performance meets forecast guidelines to launch dividend and repurchase plans
中金公司Mar 28, 2022 00:00
Saisheng Pharmaceutical (06600.HK): Profits in 2021 were slightly better than expected, focusing on pipeline clinical progress
中金公司Feb 28, 2022 00:00
Saisheng Pharmaceutical (06600.HK): Commercialization of innovative varieties that meet expectations
中金公司Aug 22, 2021 00:00
IPO News: Saisheng Pharmaceutical Holdings Limited (6600.HK)
致富證券Feb 19, 2021 00:00
No Data
No Data